Genprex (NASDAQ:GNPX) Trading Up 3.8% – Should You Buy?

Shares of Genprex (NASDAQ:GNPX) rose 3.8% during mid-day trading on Monday . The company traded as high as $0.6854 and last traded at $0.6710. Approximately 192,953 shares traded hands during trading, a decline of 23% from the average daily volume of 249,396 shares. The stock had previously closed at $0.6467.

Wall Street Analysts Forecast Growth

GNPX has been the topic of a number of research reports. Wall Street Zen upgraded shares of Genprex from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genprex in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Genprex Stock Up 3.8%

The company’s fifty day moving average is $1.04 and its two-hundred day moving average is $1.88. The firm has a market capitalization of $7.11 million, a price-to-earnings ratio of -0.05 and a beta of -0.98.

Genprex (NASDAQ:GNPX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter.

Hedge Funds Weigh In On Genprex

Several large investors have recently bought and sold shares of the business. Susquehanna International Group LLP increased its stake in Genprex by 11.7% in the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after purchasing an additional 35,661 shares in the last quarter. Manchester Financial Inc. bought a new stake in shares of Genprex during the first quarter worth $36,000. Finally, Mayflower Financial Advisors LLC bought a new stake in shares of Genprex during the first quarter worth $36,000. 14.05% of the stock is currently owned by institutional investors and hedge funds.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.